Search research articles
Contact Us
Filters
Showing results (1-10 of 57) with videos related to
Page
of 6
Sort By:
Harefuah
|
September 21, 2012
[Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals]
Ariel Hammerman, Dan Greenberg
Health Policy (Amsterdam, Netherlands)
|
June 27, 2008
Estimating the budget impact of new technologies added to the National List of Health Services in Israel: stakeholders' incentives for adopting a financial risk-sharing mechanism
Ariel Hammerman, Dan Greenberg
The American Journal of Cardiology
|
August 5, 2018
Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality
Ronen Arbel, Ariel Hammerman, Joseph Azuri
Harefuah
|
October 13, 2005
[New usage for an old drug: acetylcysteine for contrast-induced nephropathy]
Ilan Asher, Ariel Hammerman, Zev Sthoeger
The American Journal of Cardiology
|
February 4, 2019
Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Ronen Arbel, Ariel Hammerman, Joseph Azuri
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 8, 2012
Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceived interests
Ariel Hammerman, Paula Feder-Bubis, Dan Greenberg
European Journal of Preventive Cardiology
|
February 24, 2021
Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis
Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
The American Journal of Cardiology
|
May 18, 2021
Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus
Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
The American Journal of Medicine
|
January 15, 2021
Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis
Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
December 12, 2013
Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach
Arieh Gavious, Dan Greenberg, Ariel Hammerman, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 57) with videos related to
Sort By:
Page
of 6
Harefuah
|
September 21, 2012
[Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals]
Ariel Hammerman, Dan Greenberg
Health Policy (Amsterdam, Netherlands)
|
June 27, 2008
Estimating the budget impact of new technologies added to the National List of Health Services in Israel: stakeholders' incentives for adopting a financial risk-sharing mechanism
Ariel Hammerman, Dan Greenberg
The American Journal of Cardiology
|
August 5, 2018
Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality
Ronen Arbel, Ariel Hammerman, Joseph Azuri
Harefuah
|
October 13, 2005
[New usage for an old drug: acetylcysteine for contrast-induced nephropathy]
Ilan Asher, Ariel Hammerman, Zev Sthoeger
The American Journal of Cardiology
|
February 4, 2019
Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Ronen Arbel, Ariel Hammerman, Joseph Azuri
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 8, 2012
Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceived interests
Ariel Hammerman, Paula Feder-Bubis, Dan Greenberg
European Journal of Preventive Cardiology
|
February 24, 2021
Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis
Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
The American Journal of Cardiology
|
May 18, 2021
Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus
Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
The American Journal of Medicine
|
January 15, 2021
Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis
Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
December 12, 2013
Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach
Arieh Gavious, Dan Greenberg, Ariel Hammerman, et al.
Page
of 6